Alzheimer's disease (AD) is characterized by extraneuronal plaques consisting of b-amyloid (A?) peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated, paired helical filaments of the microtubule-associated protein, tau. Multiple lines of evidence suggest that overproduction of A? in the brain is a major cause of AD, whereas hyperphosphorylated tau has been found in many neurodegenerative diseases known as tauopathies. Hence, identification of new genes/proteins involved in these processes is a major goal in AD research and may provide potential therapeutic targets. In the previous funding period, we applied the random homozygous gene perturbation (RHGP) technology to screen for genes involved in A? generation and identified a novel mouse gene, Rps23r1(previously named Fg01 in the original submission). Overexpression of the RPS23R1 protein can significantly reduce A? generation, tau phosphorylation and GSK-3 activity. Further in vitro studies showed that RPS23R1 interacts with adenylate cyclases, increasing cAMP synthesis, which upregulates PKA activity. Both activation of PKA and inactivation of GSK-3 are known to inhibit A? generation and GSK-3 inactivation also inhibits tau phosphorylation. The function of Rps23r1 was also demonstrated in transgenic mice expressing brain-specific Rps23r1. Furthermore, the AD-like pathologies of the APP/PS1/tau triple transgenic AD mice were ameliorated and levels of synaptic marker proteins were increased after crossing the mice with the Rps23r1 transgenic mice. Although Rps23r1 is a unique mouse gene, Rps23r1 produces the same phenotype in cells of various species including human. Rps23r1 originated through mouse Rps23 (ribosomal protein S23) mRNA retroposition, a process where mRNA is reintegrated into the genome resulting in gene duplication/evolution. Since Rps23 retroposition also occurred in humans, it is possible that humans possess functional Rps23r1 homologs. Our results suggest that RPS23R1- and functional human RPS23R1 homolog-mediated signaling pathways may play important roles in the pathogenesis of AD and other diseases, such as cancer and diabetes, in which PKA and GSK-3 are crucially involved. Therefore, in this competitive renewal proposal we aim to determine the functional domain(s) of RPS23R1, identify functional human Rps23r1 homologs, further characterize RPS23R1 and its human homologs and decipher mechanisms underlying their effects, specifically inhibition of A generation, tau phosphorylation and modulation of GSK-3 activity. We will cross brain-specific Rps23r1 transgenic mice with AD transgenic (Tg2576 and APP/PS1/tau triple) mice to determine whether Rps23r1 can ameliorate AD-like pathologies and behavioral/cognitive deficits. We will also generate Rps23r1 conditional knockout mice to explore other physiological functions of Rps23r1. The results of these studies are expected to provide important information for developing new strategies to combat AD and other diseases.

Public Health Relevance

Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by extraneuronal plaques resulting from Ab and NFTs caused by tau phosphorylation. Our identification of the novel gene, Rps23r1, and the molecular pathway/mechanism by which it reduces Ab generation and tau phosphorylation, is expected to have a significant impact on basic research and development of new strategies for treating AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG021173-06
Application #
8234920
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Miller, Marilyn
Project Start
2002-07-01
Project End
2016-02-29
Budget Start
2012-03-15
Budget End
2013-02-28
Support Year
6
Fiscal Year
2012
Total Cost
$399,750
Indirect Cost
$194,750
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Yan, Li; Chen, Yaomin; Li, Wubo et al. (2016) RPS23RG1 reduces Aβ oligomer-induced synaptic and cognitive deficits. Sci Rep 6:18668
Zheng, Qiuyang; Zheng, Xiaoyuan; Zhang, Lishan et al. (2016) The Neuron-Specific Protein TMEM59L Mediates Oxidative Stress-Induced Cell Death. Mol Neurobiol :
Wang, Chen; Niu, Mengxi; Zhou, Zehua et al. (2016) VPS35 regulates cell surface recycling and signaling of dopamine receptor D1. Neurobiol Aging 46:22-31
Feng, Tuancheng; Niu, Mengmeng; Ji, Chengxiang et al. (2016) SNX15 Regulates Cell Surface Recycling of APP and Aβ Generation. Mol Neurobiol 53:3690-701
Huang, Timothy Y; Zhao, Yingjun; Li, Xiaoguang et al. (2016) SNX27 and SORLA Interact to Reduce Amyloidogenic Subcellular Distribution and Processing of Amyloid Precursor Protein. J Neurosci 36:7996-8011
Barini, Erica; Antico, Odetta; Zhao, Yingjun et al. (2016) Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy. Mol Neurodegener 11:16
Zhang, Cuilin; Shi, Zhun; Zhang, Lingzhi et al. (2016) Appoptosin interacts with mitochondrial outer-membrane fusion proteins and regulates mitochondrial morphology. J Cell Sci 129:994-1002
Zhao, Yingjun; Tseng, I-Chu; Heyser, Charles J et al. (2015) Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis. Neuron 87:963-75
Kanekiyo, Takahisa; Xu, Huaxi; Bu, Guojun (2014) ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Neuron 81:740-54
Zhang, Xian; Li, Yanfang; Xu, Huaxi et al. (2014) The γ-secretase complex: from structure to function. Front Cell Neurosci 8:427

Showing the most recent 10 out of 46 publications